کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6271336 | 1614749 | 2016 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Therapeutic benefits of combined treatment with tissue plasminogen activator and 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside in an animal model of ischemic stroke
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
TdTmNSStPATTCMCAO2,3,5-triphenyltetrazolium chloride - 2،3،5-trihenyltetrazolium chloridemiddle cerebral artery occlusion - انسداد شریان (سرخرگ) مغزی میانیterminal deoxynucleotidyl transferase - ترمینال deoxynucleotidyl transferasecomputerized tomography - توموگرافی کامپیوتریPositron emission tomography - توموگرافی گسیل پوزیترونintravenously - داخل وریدیThrombolytic therapy - درمان ترومبولیتیکIschemic stroke - سکته مغزی ایسکمیکtissue plasminogen activator - فعال کننده بافتی پلاسمینوژنSUV - ماشین شاسی بلندNeuroprotection - محافظت نورونی یا محافظت از عصبstandardized uptake value - مقدار جذب استاندارد شدهmodified neurological severity score - نمره شدت نورولوژیک اصلاح شدهPET - پتPropidium iodide - پروتئین یدید
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
علوم اعصاب (عمومی)
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Therapeutic benefits of combined treatment with tissue plasminogen activator and 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside in an animal model of ischemic stroke Therapeutic benefits of combined treatment with tissue plasminogen activator and 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside in an animal model of ischemic stroke](/preview/png/6271336.png)
چکیده انگلیسی
Tissue plasminogen activator (tPA) is the only approved therapy for acute ischemic stroke, but tPA therapy is limited by a short therapeutic window and some adverse side effects. 2-(4-Methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside, a salidroside analog (code-named SalA-4g), has shown potent neuroprotective effects. In this study, a rat model of embolic middle cerebral artery occlusion (MCAO) was used to mimic ischemic stroke. The embolic MCAO rats were intravenously (iv) injected with tPA alone, SalA-4g alone, or a combination of tPA and SalA-4g. Compared to treatment with tPA alone at 4 h post MCAO, combined treatment with tPA at 4 h post MCAO and SalA-4g starting at 4 h post MCAO and continuing for 3 days at an interval of 24 h significantly reduced neurological deficits and infarct volume, and significantly inhibited the intracerebral bleeding, edema formation, neuronal loss, and cellular apoptosis in the ischemic brain. Our results suggested that additive neuroprotective actions of SalA-4g contributed to widening the therapeutic window of tPA therapy and ameliorating its side effects in treating MCAO rats. The therapeutic benefits of combined treatment with tPA and SalA-4g for ischemic stroke might be associated with its effects on cerebral glucose metabolism.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Neuroscience - Volume 327, 7 July 2016, Pages 44-52
Journal: Neuroscience - Volume 327, 7 July 2016, Pages 44-52
نویسندگان
Shu Yu, Xin Liu, Yuntian Shen, Hui Xu, Yumin Yang, Fei Ding,